2017
DOI: 10.1016/s2352-3026(17)30026-1
|View full text |Cite
|
Sign up to set email alerts
|

Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

7
393
2
24

Year Published

2017
2017
2024
2024

Publication Types

Select...
6
3
1

Relationship

0
10

Authors

Journals

citations
Cited by 409 publications
(426 citation statements)
references
References 27 publications
7
393
2
24
Order By: Relevance
“…For this reason, useful clinical decision rules to distinguish TTP from pseudo-TMA are essential. When concerning the possibility of TTP, the PLASMIC score, which was recently proposed as a predictive tool for assessing the likelihood of severe ADAMTS13 deficiency in patients with TMA, may be useful 20. The details on PLASMIC score include that one point each awarded for the following: Platelet count <30,000/µL; Evidence of hemolysis (reticulocyte count >2.5%; undetectable haptoglobin, or indirect bili >2.0); No active cancer; No history of solid-organ or stem-cell transplant MCV <90 fl; INR <1.5; Creatinine <2.0 mg/dL.…”
Section: Discussionmentioning
confidence: 99%
“…For this reason, useful clinical decision rules to distinguish TTP from pseudo-TMA are essential. When concerning the possibility of TTP, the PLASMIC score, which was recently proposed as a predictive tool for assessing the likelihood of severe ADAMTS13 deficiency in patients with TMA, may be useful 20. The details on PLASMIC score include that one point each awarded for the following: Platelet count <30,000/µL; Evidence of hemolysis (reticulocyte count >2.5%; undetectable haptoglobin, or indirect bili >2.0); No active cancer; No history of solid-organ or stem-cell transplant MCV <90 fl; INR <1.5; Creatinine <2.0 mg/dL.…”
Section: Discussionmentioning
confidence: 99%
“…There is a scoring system that recently was developed to help clinically predict whether the patient has an ADAMST13 level of <10%. This PLASMIC score can be useful in predicting the levels of ADAMST13 to help direct treatment and facilitate early initiation of Rituximab [6]. Our patient received Rituximab on Day 2 of her hospitalization which preceded her drastic improvement.…”
Section: Discussionmentioning
confidence: 99%
“…It is therefore imperative that this association is recognized in clinical practice. Since ADAMTS13 results are not available in real time, a proposed quick guide to determine the likelihood of severely deficient ADAMTS13 activity is PLASMIC score (platelets, lysis, active cancer, stem cell or solid organ transplant, MCV, INR, creatinine): 0-4 score is associated with a low risk of severe ADAMTS13 deficiency, 5 score with intermediate risk and 6-7 scores with high risk [68].…”
Section: Discussionmentioning
confidence: 99%